scholarly journals Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups

2022 ◽  
Author(s):  
Heather J Whitaker ◽  
Ruby SM Tsang ◽  
Rachel Byford ◽  
Nick J Andrews ◽  
Julian Sherlock ◽  
...  
Keyword(s):  
Immune Response ◽  
Risk Groups ◽  
Vaccine Effectiveness ◽  
Clinical Risk ◽  
Clinical Risk Groups

scholarly journals Age Dependence of Prostate Cancer Clinical Risk Groups

2019 ◽  
Vol 105 (1) ◽  
pp. E275
Author(s):  
C.H. Feng ◽  
M.P. Huynh-Le ◽  
T.Å. Myklebust ◽  
T.B. Johannesen ◽  
A.M. Dale ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Risk Groups ◽  
Age Dependence ◽  
Clinical Risk ◽  
Clinical Risk Groups

scholarly journals Gasto farmacéutico en diabetes mellitus en una región de España según el Clinical Risk Group, 2012

2016 ◽  
Vol 15 (30) ◽  
Author(s):  
Luis Alvis Estrada ◽  
David Vivas-Consuelo ◽  
Vicent Caballer-Tarazona ◽  
Ruth Usó-Talamantes ◽  
Carla Sancho-Mestre ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Group ◽  
Risk Groups ◽  
Clinical Risk ◽  
Clinical Risk Groups

<p>Se pretende estimar la multimorbilidad asociada con diabetes mellitus tipo 2 y su relación con el gasto farmacéutico, para lo cual se realizó un estudio de corte transversal durante el año 2012. Se identificó a 350 015 individuos diabéticos, a través de códigos clínicos, usando la Clasificación Internacional de Enfermedades y el software 3M Clinical Risk Groups. Todos los pacientes fueron clasificados en cuatro grupos de morbilidad. El primer grupo corresponde al estadio inicial, el segundo grupo incluye el núcleo de multimorbilidad de pacientes en fases intermedia y avanzada, el tercer grupo incluye pacientes con diabetes y enfermedades malignas, y el último grupo es de pacientes en estado catastrófico, principalmente enfermos renales crónicos. La prevalencia bruta de diabetes fue de 6,7 %. El gasto promedio total fue de € 1257,1. La diabetes se caracteriza por una fuerte presencia de otras condiciones crónicas y tiene un gran impacto en el gasto farmacéutico.</p>

scholarly journals Immunosurveillance of childhood ALL: polymorphic interferon-γ alleles are associated with age at diagnosis and clinical risk groups

Leukemia ◽  
2004 ◽  
Vol 19 (1) ◽  
pp. 44-48 ◽  
Author(s):  
T Cloppenborg ◽  
M Stanulla ◽  
M Zimmermann ◽  
M Schrappe ◽  
K Welte ◽  
...  
Keyword(s):  
Risk Groups ◽  
Interferon Γ ◽  
Age At Diagnosis ◽  
Childhood All ◽  
Clinical Risk ◽  
Clinical Risk Groups

scholarly journals Cost-effectiveness of paediatric influenza vaccination in the Netherlands

2020 ◽  
Author(s):  
Pieter T. de Boer ◽  
Franklin C.K. Dolk ◽  
Lisa Nagy ◽  
Jan C. Wilschut ◽  
Richard Pitman ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Cost Saving ◽  
Influenza Vaccination ◽  
Vaccination Programme ◽  
Risk Groups ◽  
Inactivated Vaccine ◽  
Vaccination Strategies ◽  
Clinical Risk ◽  
Vaccine Type ◽  
Clinical Risk Groups

AbstractBackgroundThis study evaluates the cost-effectiveness of extending the Dutch influenza vaccination programme for elderly and clinical risk groups to include paediatric influenza vaccination, taking indirect protection into account.MethodsAn age-structured dynamic transmission model was used that was calibrated to influenza-associated GP visits over four seasons (2010/11 to 2013/14). The clinical and economic impact of different paediatric vaccination strategies were compared over 20 years, varying the targeted age range, the vaccine type for children and the vaccine type for elderly and clinical risk groups. Outcome measures include averted symptomatic infections and deaths, societal costs and quality-adjusted life years (QALYs), incremental cost-effectiveness ratios, and net health benefits (NHBs), using a willingness-to-pay threshold of €20,000 per QALY gained.ResultsAt an assumed coverage of 50%, adding vaccination of 2- to 17-year-olds with quadrivalent-live-attenuated influenza vaccine (Q-LAIV) to the current influenza vaccination programme was estimated to avert on average 406,270 symptomatic cases and 83 deaths per season compared to vaccination of elderly and risk groups with trivalent inactivated vaccine (TIV), and was cost-saving (cumulative 20-year savings of 36,396 QALYs and €1,680 million; NHB: 120,411 QALYs). This strategy dominated paediatric vaccination strategies targeting 2- to 6-year-olds or 2- to 12-year-olds, or paediatric vaccination strategies with TIV. The highest NHB was obtained when 2- to 17-year-olds were vaccinated with Q-LAIV and existing target groups switched from TIV to quadrivalent inactivated vaccine (NHB: 132,907 QALYs).ConclusionModelling indicates that paediatric influenza vaccination reduces the disease burden of influenza substantially and is cost-saving.

scholarly journals Predictability of pharmaceutical spending in primary health services using Clinical Risk Groups

Health Policy ◽  
2014 ◽  
Vol 116 (2-3) ◽  
pp. 188-195 ◽  
Author(s):  
David Vivas-Consuelo ◽  
Ruth Usó-Talamantes ◽  
José Luis Trillo-Mata ◽  
Maria Caballer-Tarazona ◽  
Isabel Barrachina-Martínez ◽  
...  
Keyword(s):  
Health Services ◽  
Risk Groups ◽  
Clinical Risk ◽  
Primary Health ◽  
Clinical Risk Groups ◽  
Pharmaceutical Spending ◽  
Primary Health Services

scholarly journals Relación entre la calidad de vida de los pacientes, mediante el cuestionario EuroQol-5D, y la clasificación de morbilidad Clinical Risk Groups

2015 ◽  
Vol 4 (2) ◽  
pp. 47-52
Author(s):  
Daniel Ríos García ◽  
Meritxell Calderó Solé ◽  
Manuel Pena Arnaiz ◽  
Virginia Sánchez Fernández ◽  
Jordi Real Gatius ◽  
...  
Keyword(s):  
Risk Groups ◽  
Clinical Risk ◽  
Calidad De Vida ◽  
Clinical Risk Groups ◽  
Euroqol 5D

GenitalChlamydia trachomatisInfection in Egyptian Women: Incidence among Different Clinical Risk Groups

1996 ◽  
Vol 22 (5) ◽  
pp. 467-472 ◽  
Author(s):  
Mahmoud El-Shourbagy ◽  
Karim Abd-El-Maeboud ◽  
Khaled M. Diab ◽  
Alaa El-Ghannam ◽  
Lila Nabegh ◽  
...  
Keyword(s):  
Risk Groups ◽  
Clinical Risk ◽  
Clinical Risk Groups ◽  
Egyptian Women

scholarly journals PHP45 Predictability of Pharmaceutical Spending Using Clinical Risk Groups in the Valencian Community in Valencia

2011 ◽  
Vol 14 (7) ◽  
pp. A341
Author(s):  
R. Uso Talamantes ◽  
M. Caballer Tarazona ◽  
L. Buigues Pastor ◽  
J.L. Trillo Mata ◽  
N. Guadalajara Olmeda ◽  
...  
Keyword(s):  
Risk Groups ◽  
Clinical Risk ◽  
Clinical Risk Groups ◽  
Pharmaceutical Spending

scholarly journals Clinical Risk Groups Analysis for Chronic Hypertensive Patients in Terms of ICD9-CM Diagnosis Codes

2017 ◽  
Author(s):  
Javier Fernández-Sánchez ◽  
Cristina Soguero-Ruiz ◽  
Pablo de Miguel-Bohoyo ◽  
Francisco Javier Rivas-Flores ◽  
Ángel Gómez-Delgado ◽  
...  
Keyword(s):  
Risk Groups ◽  
Hypertensive Patients ◽  
Clinical Risk ◽  
Diagnosis Codes ◽  
Clinical Risk Groups
Sign in / Sign up

Export Citation Format

Share Document